A5039100004- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- Chemokine receptors and signaling
- Nanoparticle-Based Drug Delivery
- Cancer Research and Treatments
- Cancer Cells and Metastasis
- TGF-β signaling in diseases
- CAR-T cell therapy research
- Genetic factors in colorectal cancer
- Cancer-related molecular mechanisms research
University of Chinese Academy of Sciences
2022-2024
Shanghai Institute of Materia Medica
2022-2024
Chinese Academy of Sciences
2022-2024
Abstract CKLF-like MARVEL transmembrane domain-containing protein 6 (CMTM6) is known to be a regulator of membranal programmed death ligand 1 (PD-L1) stability and factor associated with malignancy progression, but the effects mechanisms CMTM6 on tumor growth, as well its potential target for therapy, are still largely unknown. Here, we show that expression increased progression in both patients mice. Ablation significantly reduced human murine growth manner dependent T-cell immunity. Tumor...
SUMMARY Highlights B cells participate in anti-tumor immunity by influencing the intratumoral infiltration and function of T cells; CMTM6 cis-interacts with CD40 inhibits ubiquitin/proteasome-mediated degradation to maintain cell membrane levels; Loss cell-intrinsic significantly reduces signaling-mediated activation, survival, differentiation, T/B interaction immunity; deficiency leads a significant reduction activity agonists ICB therapy. In Brief Long et al. demonstrate that B-cell...
<div>Abstract<p>CKLF-like MARVEL transmembrane domain-containing protein 6 (CMTM6) is known to be a regulator of membranal programmed death ligand 1 (PD-L1) stability and factor associated with malignancy progression, but the effects mechanisms CMTM6 on tumor growth, as well its potential target for therapy, are still largely unknown. Here, we show that expression increased progression in both patients mice. Ablation significantly reduced human murine growth manner dependent...
<p>Supplementary Table and Figures S1-S21</p>
<div>Abstract<p>CKLF-like MARVEL transmembrane domain-containing protein 6 (CMTM6) is known to be a regulator of membranal programmed death ligand 1 (PD-L1) stability and factor associated with malignancy progression, but the effects mechanisms CMTM6 on tumor growth, as well its potential target for therapy, are still largely unknown. Here, we show that expression increased progression in both patients mice. Ablation significantly reduced human murine growth manner dependent...
<p>Supplementary Table and Figures S1-S21</p>
Abstract Inhibin beta A (INHBA) and its homodimer activin have pleiotropic effects on modulation of immune responses tumor progression, respectively, but it remains uncertain whether tumors may release to regulate anti-tumor immunity. As evidenced by our RNA-Seq in vitro results, the interferon-γ (IFN-γ) signaling pathway was significantly down-regulated intrinsic A. Tumor INHBA deficiency led lower expression PD-L1 induced IFN-γ, resulting poor responsiveness anti-PD-L1 therapy. On other...